Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:36:31 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



Q:VTVT - VTV THERAPEUTICS INC - http://www.vtvtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VTVT - Q4.516.04·25.000.123.6999-4.2601-15.224.257743928.605  29.0101  22.8739.60  7.3816:00:00Mar 1915 min RT 2¢

Recent Trades - Last 10 of 439
Time ETExPriceChangeVolume
16:00:00Q23.39-4.574
16:00:00Q23.39-4.571
16:00:00Q23.39-4.5743
15:59:54Q23.61-4.3526
15:59:54Q23.65-4.317
15:59:50Q23.40-4.561
15:59:41Q23.61-4.3536
15:59:38Q23.40-4.565
15:59:21Q23.61-4.3538
15:58:59Q23.40-4.5661

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-19 08:30U:VTVTNews ReleaseCANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
2024-03-13 08:00U:VTVTNews ReleasevTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
2024-03-04 08:00U:VTVTNews ReleasevTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
2024-03-01 08:00U:VTVTNews ReleasevTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
2024-02-28 08:00U:VTVTNews ReleasevTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
2024-02-22 16:00U:VTVTNews ReleaseCANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
2023-11-09 16:30U:VTVTNews ReleasevTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
2023-11-08 08:00U:VTVTNews ReleasevTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
2023-11-02 08:01U:VTVTNews ReleasevTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
2023-11-01 08:00U:VTVTNews ReleasevTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
2023-09-27 08:30U:VTVTNews ReleaseCANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19
2023-09-26 08:30U:VTVTNews ReleaseCantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer
2023-09-18 08:30U:VTVTNews ReleaseCANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA
2023-08-11 16:31U:VTVTNews ReleasevTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
2023-08-10 08:33U:VTVTNews ReleaseCantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer
2023-06-16 08:00U:VTVTNews ReleasevTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
2023-06-15 07:33U:VTVTNews ReleaseCANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
2023-05-24 09:00U:VTVTNews ReleasevTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
2023-05-11 16:15U:VTVTNews ReleasevTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update